Probiotics to Treat Visceral Obesity and Related Liver Disease

Nutrition in the Prevention and Treatment of Abdominal Obesity

Volumn , Issue , 2014, Pages 363-380

  Vajro, Pietro ^a,b   Poeta, Marco ^a   Pierri, Luca ^a   Pizza, Cristina ^a   D'Aniello, Roberta ^a   Sangermano, Maria ^a   Massa, Grazia ^a   Paolella, Giulia ^a  

^a UNIVERSITY OF SALERNO   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Gut dysbiosis; Gut liver axis; Metabolic syndrome; Microbiota; NAFLD NASH; Obesity; Probiotics

Indexed keywords

EID: 84902641420     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-407869-7.00033-7     Document Type: Chapter

References (156)

1. Adams KF, Schatzkin A, Harris TB, Kipnis V, Mouw T, Ballard-Barbash R, et al. Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71years old. N Engl J Med 2006, 355:763-778.
2. World Health Organization. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser 2000;894:i-xii, 1-253.
3. Finucane MM, Stevens GA, Cowan MJ, Danaei G, Lin JK, Paciorek CJ, et al. National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9·1million participants. Lancet 2011, 377:557-567.
4. Lobstein T, Baur L, Uauy R Obesity in children and young people: a crisis in public health. Obes Rev 2004, 5(Suppl. 1):4-104.
5. Wang Y, Lobstein T Worldwide trends in childhood overweight and obesity. Int J Pediatr Obes 2006, 1:11-25.
6. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report. Obes Res 1998, 6:51-209. National Institutes of Health.
7. Cole TJ, Bellizzi MC, Flegal KM, Dietz WH Establishing a standard definition for child overweight and obesity worldwide: international survey. BMJ 2000, 320:1240-1243.
8. Janssen I, Katzmarzyk PT, Ross R Body mass index, waist circumference, and health risk: evidence in support of current National Institutes of Health guidelines. Arch Intern Med 2002, 162:2074-2079.
9. McCarthy HD, Jarrett KV, Crawley HF The development of waist circumference percentiles in British children aged 5.0-16.9 y. Eur J Clin Nutr 2001, 55:902-907.
10. Jeong SK, Kim YK, Park JW, Shin YJ, Kim DS Impact of visceral fat on the metabolic syndrome and nonalcoholic fatty liver disease. J Korean Med Sci 2008, 23:789-795.
11. Isomaa B, Almgren P, Tuomi T, Forsén B, Lahti K, Nissén M, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001, 24:683-689.
12. Laaksonen DE, Lakka HM, Niskanen LK, Kaplan GA, Salonen JT, Lakka TA Metabolic syndrome and development of diabetes mellitus: application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study. Am J Epidemiol 2002, 156:1070-1077.
13. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001, 285:2486-2497. Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults.
14. Cook S, Weitzman A, Auinger P, Nguyen M, Dietz WH Prevalence of a metabolic syndrome phenotype in adolescents: findings from the Third National Health and Nutrition Examination Survey, 1988-1994. Arch Pediatr Adolesc Med 2003, 157:821-827.
15. Weiss R, Dziura J, Burgert TS, Tamborlane WV, Taksali SE, Yeckel CW, et al. Obesity and the metabolic syndrome in children and adolescents. N Engl J Med 2004, 350:2362-2374.
16. Cruz ML, Goran MI The metabolic syndrome in children and adolescents. Curr Diab Rep 2004, 4:53-62.
17. Sundaram SS, Zeitler P, Nadeau K The metabolic syndrome and nonalcoholic fatty liver disease in children. Curr Opin Pediatr 2009, 21:529-535.
18. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 2012, 142:1592-1609.
19. Willner IR, Waters B, Patil SR, Reuben A, Morelli J, Riely CA Ninety patients with nonalcoholic steatohepatitis: insulin resistance, familial tendency, and severity of disease. Am J Gastroenterol 2001, 96:2957-2961.
20. Goessling W, Massaro JM, Vasan RS, D'Agostino RB, Ellison RC, Fox CS Aminotransferase levels and 20-year risk of metabolic syndrome, diabetes, and cardiovascular disease. Gastroenterology 2008, 135:1935-1944.
21. Loomba R, Sirlin CB, Schwimmer JB, Lavine JE Advances in pediatric nonalcoholic fatty liver disease. Hepatology 2009, 50:1282-1293.
22. Nobili V, Svegliati-Baroni G, Alisi A, Miele L, Valenti L, Vajro P A 360-degree overview of paediatric NAFLD: recent insights. J Hepatol 2013, 58:1218-1229.
23. Vajro P, Lenta S, Pignata C, Salerno M, D'Aniello R, De Micco I, et al. Therapeutic options in pediatric non-alcoholic fatty liver disease: current status and future directions. Ital J Pediatr 2012, 17(38):55.
24. Johnson L, Mander AP, Jones LR, Emmett PM, Jebb SA Energy-dense, low-fiber, high-fat dietary pattern is associated with increased fatness in childhood. Am J Clin Nutr 2008, 87:846-854.
25. Hills AP, King NA, Armstrong TP The contribution of physical activity and sedentary behaviours to the growth and development of children and adolescents: implications for overweight and obesity. Sports Med 2007, 37:533-545.
26. Gozal D, Kheirandish-Gozal L Childhood obesity and sleep: relatives, partners, or both?-a critical perspective on the evidence. Ann N Y Acad Sci 2012, 1264:135-141.
27. Spruyt K, Molfese DL, Gozal D Sleep duration, sleep regularity, body weight, and metabolic homeostasis in school-aged children. Pediatrics 2011, 127:e345-e352.
28. Arora T, Singh S, Sharma RK Probiotics: interaction with gut microbiome and antiobesity potential. Nutrition 2013, 29:591-596.
29. Musso G, Cassader M, Olivetti C, Rosina F, Carbone G, Gambino R Association of obstructive sleep apnoea with the presence and severity of non-alcoholic fatty liver disease. A systematic review and meta-analysis. Obes Rev 2013, 14:417-431.
30. Wetherill YB, Akingbemi BT, Kanno J, McLachlan JA, Nadal A, Sonnenschein C, et al. In vitro molecular mechanisms of bisphenol A action. Reprod Toxicol 2007, 24:178-198.
31. Vandenberg LN, Hauser R, Marcus M, Olea N, Welshons WV Human exposure to bisphenol A (BPA). Reprod Toxicol 2007, 24:139-177.
32. Carwile JL, Michels KB Urinary bisphenol A and obesity: NHANES 2003-2006. Environ Res 2011, 111:825-830.
33. Wang T, Li M, Chen B, et al. Urinary Bisphenol A (BPA) concentration associates with obesity and insulin resistance. J Clin Endocrinol Metab 2012, 97:E223-E227.
34. Shankar A, Teppala S, Sabanayagam C Urinary bisphenol a levels and measures of obesity: results from the national health and nutrition examination survey 2003-2008. ISRN Endocrinol 2012, 2012:965243.
35. Trasande L, Attina TM, Blustein J Association between urinary bisphenol A concentration and obesity prevalence in children and adolescents. JAMA 2012, 308:1113-1121.
36. Bhandari R, Xiao J, Shankar A Urinary bisphenol A and obesity in US children. Am J Epidemiol 2013, 177:1263-1270.
37. Duffey KJ, Popkin BM Shifts in patterns and consumption of beverages between 1965 and 2002. Obesity (Silver Spring) 2007, 15:2739-2747.
38. Johnson RK, Frary C Choose beverages and foods to moderate your intake of sugars: the 2000 Dietary Guidelines for Americans-what's all the fuss about?. J Nutr 2001, 131:2766S-2771S.
39. Qi Q, Chu AY, Kang JH, Jensen MK, Curhan GC, Pasquale LR, et al. Sugar-sweetened beverages and genetic risk of obesity. N Engl J Med 2012, 367:1387-1396.
40. De Ruyter JC, Olthof MR, Seidell JC, Katan MB A trial of sugar-free or sugar-sweetened beverages and body weight in children. N Engl J Med 2012, 367:1397-1406.
41. Ebbeling CB, Feldman HA, Chomitz VR, Antonelli TA, Gortmaker SL, Osganian SK, et al. A randomized trial of sugar-sweetened beverages and adolescent body weight. N Engl J Med 2012, 367:1407-1416.
42. Ouyang X, Cirillo P, Sautin Y, McCall S, Bruchette JL, Diehl AM, et al. Fructose consumption as a risk factor for non-alcoholic fatty liver disease. J Hepatol 2008, 48:993-999.
43. Abdelmalek MF, Suzuki A, Guy C, Unalp-Arida A, Colvin R, Johnson RJ, et al. Increased fructose consumption is associated with fibrosis severity in patients with non- alcoholic fatty liver disease. Hepatology 2010, 51:1961-1971.
44. Million M, Lagier JC, Yahav D, Paul M Gut bacterial microbiota and obesity. Clin Microbiol Infect 2013, 19:305-313.
45. Harris K, Kassis A, Major G, Chou CJ Is the gut microbiota a new factor contributing to obesity and its metabolic disorders?. J Obes 2012, 2012:879151.
46. Machado MV, Cortez-Pinto H Gut microbiota and nonalcoholic fatty liver disease. Ann Hepatol 2012, 11:440-449.
47. Ronn M, Kullberg J, Karlsson H, Berglund J, Malmberg F, Orberg J, et al. Bisphenol A exposure increases liver fat in juvenile fructose-fed Fischer 344 rats. Toxicology 2013, 303:125-132.
48. Wagnerberger S, Spruss A, Kanuri G, Volynets V, Stahl C, Bischoff SC, et al. Toll-like receptors 1-9 are elevated in livers with fructose-induced hepatic steatosis. Br J Nutr 2012, 107:1727-1738.
49. Bergheim I, Weber S, Vos M, Krämer S, Volynets V, Kaserouni S, et al. Antibiotics protect against fructose-induced hepatic lipid accumulation in mice: role of endotoxin. J Hepatol 2008, 48:983-992.
50. Spruss A, Kanuri G, Stahl C, Bischoff SC, Bergheim I Metformin protects against the development of fructose-induced steatosis in mice: role of the intestinal barrier function. Lab Invest 2012, 92:1020-1032.
51. Vajro P, Paolella G, Fasano A Microbiota and gut-liver axis: a mini-review on their influences on obesity and obesity related liver disease. J Pediatr Gastroenterol Nutr 2013, 56:461-468.
52. Choi JJ, Eum SY, Rampersaud E, Daunert S, Abreu MT, Toborek M Exercise attenuates PCB-induced changes in the mouse gut microbiome. Environ Health Perspect 2013, 121:725-730.
53. Vajro P, Mandato C, Licenziati MR, Franzese A, Vitale DF, Lenta S, et al. Effects of Lactobacillus rhamnosus strain GG in pediatric obesity-related liver disease. J Pediatr Gastroenterol Nutr 2011, 52:740-743.
54. Turnbaugh PJ, Ley RE, Hamady M, Fraser-Liggett CM, Knight R, Gordon JI The human microbiome project. Nature 2007, 449:804-810.
55. Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, Manichanh C, et al. Human gut microbial gene catalogue established by metagenomic sequencing. Nature 2010, 464:59-65.
56. Huse SM, Ye Y, Zhou Y, Fodor AA A core human microbiome as viewed through 16S rRNA sequence clusters. PLoS One 2012, 7:34242.
57. Arumugam M, Raes J, Pelletier E, Le Paslier D, Yamada T, Mende DR, et al. Enterotypes of the human gut microbiome. Nature 2011, 473:174-180.
58. Gerritsen J, Smidt H, Rijkers GT, de Vos WM Intestinal microbiota in human health and disease: the impact of probiotics. Genes Nutr 2011, 6:209-240.
59. Ley RE, Bäckhed F, Turnbaugh P, Lozupone CA, Knight RD, Gordon JI Obesity alters gut microbial ecology. Proc Natl Acad Sci USA 2005, 102:11070-11075.
60. Tap J, Mondot S, Levenez F, Pelletier E, Caron C, Furet JP, et al. Towards the human intestinal microbiota phylogenetic core. Environ Microbiol 2009, 11:2574-2584.
61. Bervoets L, Van Hoorenbeeck K, Kortleven I, Van Noten C, Hens N, Vael C, et al. Differences in gut microbiota composition between obese and lean children: a cross-sectional study. Gut Pathog 2013, 5:10.
62. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006, 444:1027-1031.
63. Schwiertz A, Taras D, Schäfer K, Beijer S, Bos NA, Donus C, et al. Microbiota and SCFA in lean and overweight healthy subjects. Obesity (Silver spring) 2010, 18:190-195.
64. Macfarlane GT, Macfarlane S Fermentation in the human large intestine its physiologic consequences and the potential contribution of prebiotics. J Clin Gastroenterol 2011, 45(Suppl.):S120-S127.
65. Hotamisligil GS Inflammation and metabolic disorders. Nature 2006, 444:860-867.
66. Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 2007, 56:1761-1772.
67. Payne AN, Chassard C, Zimmermann M, Müller P, Stinca S, Lacroix C The metabolic activity of gut microbiota in obese children is increased compared with normal-weight children and exhibits more exhaustive substrate utilization. Nutr Diabetes 2011, 1:e12.
68. Louis P, Duncan SH, McCrae SI, Millar J, Jackson MS, Flint HJ Restricted distribution of the butyrate kinase pathway among butyrate-producing bacteria from the human colon. J Bacteriol 2004, 186:2099-2106.
69. Duncan SH, Louis P, Flint HJ Lactate-utilizing bacteria, isolated from human feces, that produce butyrate as a major fermentation product. Appl Environ Microbiol 2004, 70:5810-5817.
70. Santacruz A, Marcos A, Wärnberg J, Martí A, Martin-Matillas M, Campoy C, et al. Interplay between weight loss and gut microbiota composition in overweight adolescents. Obesity (Silver Spring) 2009, 17:1906-1915.
71. Woodard GA, Encarnacion B, Downey JR, et al. Probiotics improve outcomes after Roux-en-Y gastric bypass surgery: a prospective randomized trial. J Gastrointest Surg 2009, 13:1198-1204.
72. Sweeney TE, Morton JM The human gut microbiome: a review of the effect of obesity and surgically induced weight loss. JAMA Surg 2013, 9:1-7.
73. Zhang H, DiBaise JK, Zuccolo A, Kudrna D, Braidotti M, Yu Y, et al. Human gut microbiota in obesity and after gastric bypass. Proc Natl Acad Sci USA 2009, 106:2365-2370.
74. Li JV, Ashrafian H, Bueter M, Kinross J, Sands C, le Roux CW, et al. Metabolic surgery profoundly influences gut microbial-host metabolic cross-talk. Gut 2011, 60:1214-1223.
75. Li JV, Reshat R, Wu Q, Ashrafian H, Bueter M, le Roux CW, et al. Experimental bariatric surgery in rats generates acytotoxic chemical environment in the gut contents. Front Microbiol 2011, 2:183.
76. Turnbaugh PJ, Hamady M, Yatsunenko T, Cantarel BL, Duncan A, Ley RE, et al. A core gut microbiome in obese and lean twins. Nature 2009, 22(457):480-484.
77. Tims S, Derom C, Jonkers DM, Vlietinck R, Saris WH, Kleerebezem M, et al. Microbiota conservation and BMI signatures in adult monozygotic twins. ISME J 2013, 7:707-717.
78. Simões CD, Maukonen J, Kaprio J, Rissanen A, Pietiläinen KH, Saarela M Habitual dietary intake is associated with stool microbiota composition in monozygotic twins. J Nutr 2013, 143:417-423.
79. Koren O, Spor A, Felin J, Fåk F, Stombaugh J, Tremaroli V, et al. Human oral, gut, and plaque microbiota in patients with atherosclerosis. Proc Natl Acad Sci USA 2011, 108(Suppl. 1):4592-4598.
80. Cani PD, Delzenne NM Gut microflora as a target for energy and metabolic homeostasis. Curr Opin Clin Nutr Metab Care 2007, 10:729-734.
81. Ilan Y Leaky gut and the liver: a role for bacterial translocation in nonalcoholic steatohepatitis. World J Gastroenterol 2012, 18:2609-2618.
82. Wigg AJ, Roberts-Thomson IC, Dymock RB, McCarthy PJ, Grose RH, Cummins AG The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis. Gut 2001, 48:206-211.
83. Cani PD, Possemiers S, Van de Wiele T, Guiot Y, Everard A, Rottier O, et al. Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut 2009, 58:1091-1103.
84. Laugerette F, Vors C, Peretti N, Michalski MC Complex links between dietary lipids, endogenous endotoxins and metabolic inflammation. Biochimie 2011, 93:39-45.
85. Cani PD, Osto M, Geurts L, Everard A Involvement of gut microbiota in the development of low-grade inflammation and type 2 diabetes associated with obesity. Gut Microbes 2012, 3:279-288.
86. Li Z, Yang S, Lin H, Huang J, Watkins PA, Moser AB, et al. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology 2003, 37:343-350.
87. Zhu L, Baker SS, Gill C, Liu W, Alkhouri R, Baker RD, et al. Characterization of the gut microbiome in non-alcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. Hepatology 2012, 57:6019.
88. Nair S, Cope K, Risby TH, Diehl AM Obesity and female gender increase breath ethanol concentration: potential implications for the pathogenesis of nonalcoholic steatohepatitis. Am J Gastroenterol 2001, 96:1200-1204.
89. Compare D, Coccoli P, Rocco A, Nardone OM, De Maria S, Cartenì M, et al. Gut-liver axis: the impact of gut microbiota on non alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis 2012, 22:471-476.
90. Dumas ME, Barton RH, Toye A, Cloarec O, Blancher C, Rothwell A, et al. Metabolic profiling reveals a contribution of gutmicrobiota to fatty liver phenotype in insulin-resistant mice. Proc Natl Acad Sci USA 2006, 103:12511-12516.
91. Claus SP, Tsang TM, Wang Y, Cloarec O, Skordi E, Martin FP, et al. Systemic multicompartmental effects of the gut microbiome on mouse metabolic phenotypes. Mol Syst Biol 2008, 4:219.
92. Fuchs M Non-alcoholic fatty liver disease: the bile acid-activated farnesoid x receptor as an emerging treatment target. J Lipids 2012, 2012:934396.
93. Basciano H, Federico L, Adeli K Fructose, insulin resistance, and metabolic dyslipidemia. Nutr Metab (Lond) 2005, 2:5.
94. Maier IB, Stricker L, Ozel Y, Wagnerberger S, Bischoff SC, Bergheim I A low fructose diet in the treatment of pediatric obesity: a pilot study. Pediatr Int 2011, 53:303-308.
95. Curry DL Effects of mannose and fructose on the synthesis and secretion of insulin. Pancreas 1989, 4:2-9.
96. Dekker MJ, Su Q, Baker C, Rutledge AC, Adeli K Fructose: a highly lipogenic nutrient implicated in insulin resistance, hepatic steatosis, and the metabolic syndrome. Am J Physiol Endocrinol Metab 2010, 299:E685-E694.
97. Flanagan DE, Evans ML, Monsod TP, Rife F, Heptulla RA, Tamborlane WV, et al. The influence of insulin on circulating ghrelin. Am J Physiol 2003, 284:E313-E316.
98. Teff KL, Elliott SS, Tschöp M, Kieffer TJ, Rader D, Heiman M, et al. Dietary fructose reduces circulating insulin and leptin, attenuates postprandial suppression of ghrelin, and increases triglycerides in women. J Clin Endocrinol Metab 2004, 89:2963-2972.
99. Haub S, Kanuri G, Volynets V, Brune T, Bischoff SC, Bergheim I Serotonin reuptake transporter (SERT) plays a critical role in the onset of fructose-induced hepatic steatosis in mice. Am J Physiol Gastrointest Liver Physiol 2010, 298:G335-G344.
100. Havel PJ Dietary fructose: implications for dysregulation of energy homeostasis and lipid/ carbohydrate metabolism. Nutr Rev 2005, 63:133-157.
101. Schrezenmeir J, de Vrese M Probiotics, prebiotics, and synbiotics-approaching a definition. Am J Clin Nutr 2001, 73:361S-364S.
102. Guarner F, Schaafsma GJ Probiotics. Int J Food Microbiol 1998, 39:237-238.
103. Roberfroid M Prebiotics: the concept revisited. J Nutr 2007, 137:830S-837S.
104. Safavi M, Farajian S, Kelishadi R, Mirlohi M, Hashemipour M The effects of synbiotic supplementation on some cardio-metabolic risk factors in overweight and obese children: a randomized triple-masked controlled trial. Int J Food Sci Nutr 2013, 64(6):687-693.
105. Thomas DW, Greer FR American academy of pediatrics committee on nutrition; American academy of pediatrics section on gastroenterology, hepatology, and nutrition. Probiotics and prebiotics in pediatrics. Pediatrics 2010, 126:1217-1231.
106. Cani PD Gut microbiota and obesity: lessons from the microbiome. Brief Funct Genomics 2013, 2(4):381-387.
107. Lee HY, Park JH, Seok SH, Baek MW, Kim DJ, Lee KE, et al. Human originated bacteria, Lactobacillus rhamnosus PL60, produce conjugated linoleic acid and show anti-obesity effects in diet induced obese mice. Biochim Biophys Acta 2006, 1761:736-744.
108. Esposito E, Iacono A, Bianco G, Autore G, Cuzzocrea S, Vajro P, et al. Probiotics reduce the inflammatory response induced by a highfatdiet in the liver of young rats. J Nutr 2009, 139:905-911.
109. Murphy EF, Cotter PD, Hogan A, o'Sullivan O, Joyce A, Fouhy F, et al. Divergent metabolic outcomes arising from targeted manipulation of the gut microbiota in diet induced obesity. Gut 2013, 62:220-226.
110. Arora T, Anastasovska J, Gibson G, Tuohy K, Sharma RK, Bell J, et al. Effect of Lactobacillus acidophilus NCDC 13 supplementation on the progression of obesity in diet-induced obese mice. Br J Nutr 2012, 108:1382-1389.
111. Park DY, Ahn YT, Park SH, Huh CS, Yoo SR, Yu R, et al. Supplementation of Lactobacillus curvatus HY7601 and Lactobacillus plantarum KY1032 in diet-induced obese mice is associated with gut microbial changes and reduction in obesity. PLoS One 2013, 8:e59470.
112. Everard A, Belzer C, Geurts L, Ouwerkerk JP, Druart C, Bindels LB, et al. Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proc Natl Acad Sci USA 2013, 110:9066-9071.
113. Mischke M, Plosch T More than just a gut instinct-The potential interplay between a baby's nutrition, its gut microbiome and the epigenome. Am J Physiol Regul Integr Comp Physiol 2013, 304:R1065-R1069.
114. Chouraqui JP, Grathwohl D, Labaune JM, Hascoet JM, de Montgolfier I, Leclaire M, et al. Assessment of the safety, tolerance, and protective effect against diarrhea of infant formulas containing mixtures of probiotics or probiotics and prebiotics in a randomized controlled trial. Am J Clin Nutr 2008, 87:1365-1373.
115. Maldonado J, Lara-Villoslada F, Sierra S, Sempere L, Gómez M, Rodriguez JM, et al. Safety and tolerance of the human milk probiotic strain Lactobacillus salivarius CECT5713 in 6-month-old children. Nutrition 2010, 26:1082-1087.
116. Robinson EL, Thompson WL Experimental feeding tests with Lactobacillus acidophilus. Am J Dis Child 1952, 84:757-758.
117. Scalabrin DM, Johnston WH, Hoffman DR, P'Pool VL, Harris CL, Mitmesser SH Growth and tolerance of healthy term infants receiving hydrolyzed infant formulas supplemented with Lactobacillus rhamnosus GG: randomized, double-blind, controlled trial. Clin Pediatr (Phila) 2009, 48:734-744.
118. Vendt N, Grünberg H, Tuure T, Malminiemi O, Wuolijoki E, Tillmann V, et al. Growth during the first 6 months of life in infants using formula enriched with Lactobacillus rhamnosus GG: double-blind, randomized trial. J Hum Nutr Diet 2006, 19:51-58.
119. de Roos NM, Schouten G, Katan MB Yoghurt enriched with Lactobacillus acidophilus does not lower blood lipids in healthy men and women with normal toborderline high serum cholesterol levels. Eur J Clin Nutr 1999, 53:277-280.
120. Sadrzadeh-Yeganeh H, Elmadfa I, Djazayery A, Jalali M, Heshmat R, Chamary M The effects of probiotic and conventional yoghurt on lipid profile in women. Br J Nutr 2010, 103:1778-1783.
121. Chang BJ, Park SU, Jang YS, Ko SH, Joo NM, Kim SI, et al. Effect of functional yogurt NY-YP901 in improving the trait of metabolic syndrome. Eur J Clin Nutr 2011, 65:1250-1255.
122. Sanz Y, Rastmanesh R, Agostoni C Understanding the role of gut microbes and probiotics in obesity: how far are we?. Pharmacol Res 2013, 69:144-155.
123. Leber B, Tripolt NJ, Blattl D, Eder M, Wascher TC, Pieber TR, et al. The influence of probiotic supplementation on gut permeability in patients with metabolic syndrome: an open label, randomized pilot study. Eur J Clin Nutr 2012, 66:1110-1115.
124. Agerholm-Larsen L, Raben A, Haulrik N, Hansen AS, Manders M, Astrup A Effect of 8week intake of probiotic milk products on risk factors for cardiovascular diseases. Eur J Clin Nutr 2000, 54:288-297.
125. Bukowska H, Pieczul-Mroz J, Jastrzebska M, Chełstowski K, Naruszewicz M Decrease in fibrinogen and LDL-cholesterol levels upon supplementation of diet with Lactobacillus plantarumin subjects with moderately elevated cholesterol. Atherosclerosis 1998, 137:437-438.
126. Naruszewicz M, Johansson ML, Zapolska-Downar D, Bukowska H Effect of Lactobacillus plantarum299v on cardiovascular disease risk factors in smokers. Am J Clin Nutr 2002, 76:1249-1255.
127. Laitinen K, Poussa T, Isolauri E. Probiotics and dietary counselling contribute to glucose regulation during and after pregnancy: a randomised controlled trial. Br J Nutr 2009, 101:1679-1687. Nutrition, allergy, mucosal immunology and intestinal microbiota group.
128. Ilmonen J, Isolauri E, Poussa T, Laitinen K Impact of dietary counseling and probiotic intervention on maternal anthropometric measurements during and after pregnancy: a randomized placebo-controlled trial. Clin Nutr 2011, 30:156-164.
129. Gobel RJ, Larsen N, Jakobsen M, Molgaard C, Michaelsen KF Probiotics to obese adolescents; RCT examining the effects on inflammation and metabolic syndrome. J Pediatr Gastroenterol Nutr 2012, 55:673-678.
130. Aller R, De Luis DA, Izaola O, Conde R, Gonzalez Sagrado M Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patients: a double blind randomized clinical trial. Eur Rev Med Pharmacol Sci 2011, 15:1090-1095.
131. Jung SP, Lee KM, Kang JH, Yun SI, Park HO, Moon Y, et al. Effect of Lactobacillus gasseri BNR17 on overweight and obese adults: a randomized, double-blind clinical trial. Korean J Fam Med 2013, 34:80-89.
132. Kadooka Y, Sato M, Imaizumi K, Ogawa A, Ikuyama K, Akai Y, et al. Regulation of abdominal adiposity by probiotics (Lactobacillus gasseriSBT2055) in adults with obese tendencies in a randomized controlled trial. Eur J Clin Nutr 2010, 64:636-643.
133. Li DY, Yang M, Edwards S, Ye SQ. Nonalcoholic fatty liver disease: for better or worse, blame the gut microbiota? JPEN J Parenter Enteral Nutr 2013 [Epub ahead of print].
134. Ma X, Hua J, Li Z Probiotics improve high fat diet-induced hepatic steatosis and insulin resistance by increasing hepatic NKT cells. J Hepatol 2008, 49:821-830.
135. Velayudham A, Dolganiuc A, Ellis M, Petrasek J, Kodys K, Mandrekar P, et al. VSL#3 probiotic treatment attenuates fibrosis without changes in steatohepatitis in a diet-induced nonalcoholic steatohepatitis model in mice. Hepatology 2009, 49:989-997.
136. Mencarelli A, Cipriani S, Renga B, Bruno A, D'Amore C, Distrutti E, et al. VSL#3 resets insulin signaling and protects against NASH and atherosclerosis in a model of genetic dys lipidemia and intestinal inflammation. PLoS One 2012, 7:e45425.
137. Yadav H, Jain S, Sinha PR Antidiabetic effect of probiotic dahi containing Lactobacillus acidophilus and Lactobacillus casei in high fructose fed rats. Nutrition 2007, 23:62-68.
138. Xu RY, Wan YP, Fang QY, Lu W, Cai W Supplementation with probiot ics modifies gut flora and attenuates liver fat accumulation in rat nonalco holic fatty liver disease model. J Clin Biochem Nutr 2012, 50:72-77.
139. Yoo SR, Kim YJ, Park DY, Jung UJ, Jeon SM, Ahn YT, et al. Probiotics L. plantarum and L. curvatus in combination alter hepatic lipidmetabolism and suppress diet-induced obesity. Obesity (Silver Spring) 2013 [Epub ahead of print].
140. Lirussi F, Mastropasqua E, Orando S, Orlando R Probiotics for non-alcoholic fatty liver disease and/or steatohepatitis. Cochrane Database Syst Rev 2007, CD005165.
141. Loguercio C, De Simone T, Federico A, Terracciano F, Tuccillo C, Di Chicco M, et al. Gut-liver axis: a new point of attack to treat chronic liver damage?. Am J Gastroenterol 2002, 97:2144-2146.
142. Loguercio C, Federico A, Tuccillo C, Terracciano F, D'Auria MV, De Simone C, et al. Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases. J Clin Gastroenterol 2005, 39:540-543.
143. Socha P, Horvath A, Vajro P, Dziechciarz P, Dhawan A, Szajewska H Pharmacological interventions for nonalcoholic fatty liver disease in adults and in children: a systematic review. J Pediatr Gastroenterol Nutr 2009, 48:587-596.
144. Malaguarnera M, Vacante M, Antic T, Giordano M, Chisari G, Acquaviva R, et al. Bifidobacterium longum with fructo-oligosaccharides in patients with non alcoholic steatohepatitis. Dig Dis Sci 2012, 57:545-553.
145. Mouzaki M, Comelli EM, Arendt BM, Bonengel J, Fung SK, Fischer SE, et al. Intestinal microbiota in patients with nonalcoholic fatty liver disease. Hepatology 2013, 58(1):120-127.
146. Vrieze A, Van Nood E, Holleman F, Salojärvi J, Kootte RS, Bartelsman JF, et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology 2012, 143:913-916e7.
147. Armougom F, Henry M, Vialettes B, Raccah D, Raoult D Monitoring bacterial community of human gut microbiota reveals an increase in Lactobacillus in obese patients and Methanogens in anorexic patients. PLoS One 2009, 4:e7125.
148. Nadal I, Santacruz A, Marcos A, Warnberg J, Garagorri JM, Moreno LA, et al. Shifts in clostridia, bacteroides and immunoglobulin-coating fecal bacteria associated with weight loss in obese adolescents. Int J Obes (Lond) 2009, 33:758-767.
149. Balamurugan R, George G, Kabeerdoss J, Hepsiba J, Chandragunasekaran AM, Ramakrishna BS Quantitative differences in intestinal Faecalibacterium prausnitzii in obese Indian children. Br J Nutr 2010, 103:335-338.
150. Million M, Maraninchi M, Henry M, Armougom F, Raoult D Obesity-associated Gut microbiota is enriched in Lactobacillus reuteri and depleted in Bifidobacterium animalis and Methanobrevibacter smithii. Int J Obes 2011, 36:817-825.
151. Kalliomäki M, Collado MC, Salminen S, Isolauri E Early differences in fecal microbiota composition in children may predict overweight. Am J Clin Nutr 2008, 87:534-538.
152. Million M, Angelakis E, Maraninchi M, Henry M, Giorgi R, Valero R, et al. Correlation between body mass index and gut concentrations of Lactobacillus reuteri, Bifidobacterium Animalis, Methanobrevibacter smithii and Escherichia coli. Int J Obes 2013, 1-7.
153. Million M, Angelakis E, Paul M, Armougom F, Leibovici L, Raoult D Comparative meta-analysis of the effect of Lactobacillus species on weight gain in humans and animals. Microb Pathog 2012, 53:100-108.
154. Fabian E, Elmadfa I The effect of daily consumption of probiotic and conventional yoghurt on oxidant and antioxidant parameters in plasma of young healthy women. Int J Vitam Nutr Res 2007, 77:79-88.
155. Wong VW, Won GL, Chim AM, Chu WC, Yeung DK, Li KC, et al. Treatment of nonalcoholic steatohepatitis with probiotics. A proof-of-concept study. Ann Hepatol 2013, 12:256-262.
156. Ma YY, Li L, Yu CH, Shen Z, Chen LH, Li YM Effects of probiotics on nonalcoholic fatty liver disease: A meta-analysis. World J Gastroenterol 2013, 19:6911-6918.